Is there a space for incretin mimetics as a therapy for excess weight, obesity and cardiometabolic disease prevention?

10 p.

Autores:: Lopez-Jaramillo, Patricio
Di Stefano, Karina A.
Velásquez, Elizabeth
Camacho López, Paul Anthony
López López, Jose

Tipo de recurso:: Article of journal

Fecha de publicación:: 2016

Institución:: Universidad de Santander

Repositorio:: Repositorio Universidad de Santander

Idioma:: spa

id	RUDES2_69c12b3fba769407a586b655cfbd40df
oai_identifier_str	oai:repositorio.udes.edu.co:001/3234
network_acronym_str	RUDES2
network_name_str	Repositorio Universidad de Santander
repository_id_str
dc.title.eng.fl_str_mv	Is there a space for incretin mimetics as a therapy for excess weight, obesity and cardiometabolic disease prevention?
dc.title.alternative.spa.fl_str_mv	¿Existe un espacio para los análogos de la incretina como terapia para el sobrepeso, la obesidad y la prevención de la enfermedad cardio-metabólica?
title	Is there a space for incretin mimetics as a therapy for excess weight, obesity and cardiometabolic disease prevention?
spellingShingle	Is there a space for incretin mimetics as a therapy for excess weight, obesity and cardiometabolic disease prevention? Enfermedad cardiovascular Mortalidad Cardiovascular disease Death
title_short	Is there a space for incretin mimetics as a therapy for excess weight, obesity and cardiometabolic disease prevention?
title_full	Is there a space for incretin mimetics as a therapy for excess weight, obesity and cardiometabolic disease prevention?
title_fullStr	Is there a space for incretin mimetics as a therapy for excess weight, obesity and cardiometabolic disease prevention?
title_full_unstemmed	Is there a space for incretin mimetics as a therapy for excess weight, obesity and cardiometabolic disease prevention?
title_sort	Is there a space for incretin mimetics as a therapy for excess weight, obesity and cardiometabolic disease prevention?
dc.creator.fl_str_mv	Lopez-Jaramillo, Patricio Di Stefano, Karina A. Velásquez, Elizabeth Camacho López, Paul Anthony López López, Jose
dc.contributor.author.spa.fl_str_mv	Lopez-Jaramillo, Patricio Di Stefano, Karina A. Velásquez, Elizabeth Camacho López, Paul Anthony López López, Jose
dc.subject.proposal.spa.fl_str_mv	Enfermedad cardiovascular Mortalidad
topic	Enfermedad cardiovascular Mortalidad Cardiovascular disease Death
dc.subject.proposal.eng.fl_str_mv	Cardiovascular disease Death
description	10 p.
publishDate	2016
dc.date.issued.spa.fl_str_mv	2016-01
dc.date.accessioned.spa.fl_str_mv	2019-06-28T20:18:19Z
dc.date.available.spa.fl_str_mv	2019-06-28T20:18:19Z
dc.type.spa.fl_str_mv	Artículo de revista
dc.type.coar.fl_str_mv	http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.coarversion.fl_str_mv	http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.spa.fl_str_mv	http://purl.org/coar/resource_type/c_6501
dc.type.content.spa.fl_str_mv	Text
dc.type.driver.spa.fl_str_mv	info:eu-repo/semantics/article
dc.type.redcol.spa.fl_str_mv	http://purl.org/redcol/resource_type/ART
dc.type.version.spa.fl_str_mv	info:eu-repo/semantics/publishedVersion
format	http://purl.org/coar/resource_type/c_6501
status_str	publishedVersion
dc.identifier.doi.spa.fl_str_mv	10.1016/j.rccar.2015.10.003
dc.identifier.issn.spa.fl_str_mv	0120-5633
dc.identifier.uri.spa.fl_str_mv	https://repositorio.udes.edu.co/handle/001/3234
identifier_str_mv	10.1016/j.rccar.2015.10.003 0120-5633
url	https://repositorio.udes.edu.co/handle/001/3234
dc.language.iso.spa.fl_str_mv	spa
language	spa
dc.relation.ispartof.spa.fl_str_mv	Revista Colombiana de Cardiología
dc.rights.spa.fl_str_mv	Derechos Reservados - Sociedad Colombiana de Cardiología y Cirugía Cardiovascular, 2016
dc.rights.coar.fl_str_mv	http://purl.org/coar/access_right/c_abf2
dc.rights.accessrights.spa.fl_str_mv	info:eu-repo/semantics/openAccess
dc.rights.creativecommons.spa.fl_str_mv	Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0)
dc.rights.uri.spa.fl_str_mv	https://creativecommons.org/licenses/by-nc/4.0/
rights_invalid_str_mv	Derechos Reservados - Sociedad Colombiana de Cardiología y Cirugía Cardiovascular, 2016 Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0) https://creativecommons.org/licenses/by-nc/4.0/ http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv	openAccess
dc.format.mimetype.spa.fl_str_mv	application/pdf
dc.source.eng.fl_str_mv	https://www.elsevier.es/es-revista-revista-colombiana-cardiologia-203-pdf-S0120563315002211
institution	Universidad de Santander
bitstream.url.fl_str_mv	https://repositorio.udes.edu.co/bitstreams/708b0f5b-a443-4e3b-9435-928f6adc12a1/download https://repositorio.udes.edu.co/bitstreams/b8dd90b0-ccd8-4963-96dd-a944fab85c41/download https://repositorio.udes.edu.co/bitstreams/5d73f6a7-113c-4455-bb4a-423ca505a055/download https://repositorio.udes.edu.co/bitstreams/8dd57dc9-71c6-466a-bfa7-eaebbe665117/download https://repositorio.udes.edu.co/bitstreams/100ee7df-01ca-4c2e-b4a9-6fa7f8be8b65/download
bitstream.checksum.fl_str_mv	4c0ef59ea632f884b36477a43cefbd22 111f3f89051ce78b95987882d741145e 38d94cf55aa1bf2dac1a736ac45c881c 1b6f397982fa43693e2bf6e93ffa24fd 5dbe86c1111d64f45ba435df98fdc825
bitstream.checksumAlgorithm.fl_str_mv	MD5 MD5 MD5 MD5 MD5
repository.name.fl_str_mv	Repositorio Universidad de Santander
repository.mail.fl_str_mv	soporte@metabiblioteca.com
_version_	1814158575829778432
spelling	Lopez-Jaramillo, Patricio9a71267b-dcb0-4d31-b37d-2d30be58d4d2-1Di Stefano, Karina A.772af662-3e27-468a-af87-05f03a4a4f74-1Velásquez, Elizabeth6d4b2c08-1c6f-4114-a591-71cc69849322-1Camacho López, Paul Anthony594e3832-d941-4df3-b3cc-a2c088dca74c-1López López, Jose2fc3ec26-9cd2-471d-89d5-f48d8bb85a9b-12019-06-28T20:18:19Z2019-06-28T20:18:19Z2016-0110 p.Introduction: During the last decades there has been a gradual increase of cardiovascular diseases, who have become the main cause of death in the world and especially in Latin American countries, despite having identified preventable cardiovascular risk factors that explain around 90% of myocardial infarctions and cerebrovascular accidents. Therefore, it is require to implement actions that will allow to control cardiovascular risk factors, including being overweight or obese. Motivation: To review the effect of GLP-1 receptor agonists, including liraglutide, in controlling cardiovascular risk factors, particularly excess weight and obesity and the subsequent prevention of cardiovascular diseases. Methods: Evidence were searched by means of boolean operators and cross references in databases MEDLINE, LILACS and Google Scholar. Conclusions: GLP-1 receptor agonists can be a pharmacological alternative to control excess weight and obesity, and may help in preventing cardiovascular disease, though some questions remain regarding the benefits of its use in our field.Introducción: En las últimas décadas se ha producido un aumento progresivo de la enfermedad cardiovascular, convirtiéndose en la principal causa de mortalidad en el mundo y especialmente en los países de Latinoamérica, a pesar de haberse identificado los factores de riesgo cardiovascular prevenibles y que explican alrededor del 90% de la causalidad de un infarto de miocardio y de un accidente cerebrovascular. Por tanto, es necesario implementar las acciones que permitan controlar los factores de riesgo cardiovascular incluyendo sobrepeso y obesidad. Objetivo: Revisar el efecto que tienen los análogos de los receptores del GLP-1, entre ellos la liraglutida, en el control de factores de riesgo cardiovascular, particularmente del sobrepeso y la obesidad y en la consecuente prevención de la enfermedad cardiovascular. Métodos: Se realizó una búsqueda de la evidencia con operadores booleanos y referencias cruzadas en base de datos MEDLINE, LILACS y Google Scholar. Conclusiones: Los análogos de los receptores de GLP-1 pueden ser una alternativa farmacológica para el manejo del sobrepeso, la obesidad y contribuir en la prevención de la enfermedad cardiovascular, aunque todavía quedan interrogantes sobre el beneficio de su uso en nuestro medio.application/pdf10.1016/j.rccar.2015.10.0030120-5633https://repositorio.udes.edu.co/handle/001/3234spaRevista Colombiana de CardiologíaDerechos Reservados - Sociedad Colombiana de Cardiología y Cirugía Cardiovascular, 2016info:eu-repo/semantics/openAccessAtribución-NoComercial 4.0 Internacional (CC BY-NC 4.0)https://creativecommons.org/licenses/by-nc/4.0/http://purl.org/coar/access_right/c_abf2https://www.elsevier.es/es-revista-revista-colombiana-cardiologia-203-pdf-S0120563315002211Enfermedad cardiovascularMortalidadCardiovascular diseaseDeathIs there a space for incretin mimetics as a therapy for excess weight, obesity and cardiometabolic disease prevention?¿Existe un espacio para los análogos de la incretina como terapia para el sobrepeso, la obesidad y la prevención de la enfermedad cardio-metabólica?Artículo de revistahttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1Textinfo:eu-repo/semantics/articlehttp://purl.org/redcol/resource_type/ARTinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/version/c_970fb48d4fbd8a85PublicationTHUMBNAILIs there a space for incretin mimetics as a therapy for excess weight, obesity and cardiometabolic disease prevention..pdf.jpgIs there a space for incretin mimetics as a therapy for excess weight, obesity and cardiometabolic disease prevention..pdf.jpgGenerated Thumbnailimage/jpeg1788https://repositorio.udes.edu.co/bitstreams/708b0f5b-a443-4e3b-9435-928f6adc12a1/download4c0ef59ea632f884b36477a43cefbd22MD54Is there a space for incretin mimetics as a therapy for excess weight, obesity and cardiometabolic disease prevention.pdf.jpgIs there a space for incretin mimetics as a therapy for excess weight, obesity and cardiometabolic disease prevention.pdf.jpgGenerated Thumbnailimage/jpeg15054https://repositorio.udes.edu.co/bitstreams/b8dd90b0-ccd8-4963-96dd-a944fab85c41/download111f3f89051ce78b95987882d741145eMD58LICENSElicense.txtlicense.txttext/plain; charset=utf-859https://repositorio.udes.edu.co/bitstreams/5d73f6a7-113c-4455-bb4a-423ca505a055/download38d94cf55aa1bf2dac1a736ac45c881cMD52ORIGINALIs there a space for incretin mimetics as a therapy for excess weight, obesity and cardiometabolic disease prevention.pdfArtículo Principalapplication/pdf942157https://repositorio.udes.edu.co/bitstreams/8dd57dc9-71c6-466a-bfa7-eaebbe665117/download1b6f397982fa43693e2bf6e93ffa24fdMD57TEXTIs there a space for incretin mimetics as a therapy for excess weight, obesity and cardiometabolic disease prevention.pdf.txtIs there a space for incretin mimetics as a therapy for excess weight, obesity and cardiometabolic disease prevention.pdf.txtExtracted texttext/plain5https://repositorio.udes.edu.co/bitstreams/100ee7df-01ca-4c2e-b4a9-6fa7f8be8b65/download5dbe86c1111d64f45ba435df98fdc825MD56001/3234oai:repositorio.udes.edu.co:001/32342023-10-10 09:23:25.078https://creativecommons.org/licenses/by-nc/4.0/Derechos Reservados - Sociedad Colombiana de Cardiología y Cirugía Cardiovascular, 2016https://repositorio.udes.edu.coRepositorio Universidad de Santandersoporte@metabiblioteca.comTGljZW5jaWEgZGUgUHVibGljYWNpw7NuIFVERVMKRGlyZWN0cmljZXMgZGUgVVNPIHkgQUNDRVNPCgo=

Is there a space for incretin mimetics as a therapy for excess weight, obesity and cardiometabolic disease prevention?

Publicaciones similares